RNS Number : 0791I MaxCyte, Inc. 10 August 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options Gaithersburg, Maryland - 10 August 2021 : MaxCyte (Nasdaq: MXCT) (LSE: MXCT, MXCN) , a leading provider of cell-engineering
RNS Number : 9261H MaxCyte, Inc. 09 August 2021 MaxCyte Signs Clinical and Commercial License with Sana Biotechnology Agreement represents MaxCyte's 14 th strategic platform license (SPL) Sana will use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform in conjunction
RNS Number : 7572H MaxCyte, Inc. 05 August 2021 Amendments to Bylaws GAITHERSBURG, MD , August 5, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company "), a leading provider of cell-engineering platform technologies, announces that it has filed amended
RNS Number : 4604H MaxCyte, Inc. 03 August 2021 MaxCyte Announces Closing of Offering and Resulting Total Voting Rights This announcement contains inside information GAITHERSBURG, MD , August 3, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company
RNS Number : 1620H MaxCyte, Inc. 02 August 2021 MaxCyte Announces Full Exercise of Over-Allotment Option This announcement contains inside information GAITHERSBURG, MD , August 2, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company "), a leading
RNS Number : 1359H MaxCyte, Inc. 30 July 2021 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
RNS Number : 1349H MaxCyte, Inc. 30 July 2021 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered
RNS Number : 0400H MaxCyte, Inc. 30 July 2021 MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market This announcement contains inside information GAITHERSBURG, MD , July 29, 2021 - MaxCyte, Inc.
RNS Number : 4538G MaxCyte, Inc. 26 July 2021 MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market This announcement contains inside information GAITHERSBURG, MD , July 26, 2021 - MaxCyte, Inc. , (LSE: MXCT, MXCN), a leading provider of platform
RNS Number : 6950F MaxCyte, Inc. 19 July 2021 Termination of depositary interest facility and transition to CREST depository interests GAITHERSBURG, MD , 19 July 2021 - MaxCyte, Inc. (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announces certain
